Clinical trials: Primary Headache Disorders
Migraine
A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine
The main purpose of this study is to determine the efficacy of the study drug Galcanezumab in Japanese participants with episodic migraine.
- Trial name
- NCT02959177
- Testing
- Galcanezumab
- Where
- 47 sites in Japan
- Volunteers
- 459 people
- Sponsor
- Eli Lilly and Company
Migraine, Migraine Disorders
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
This is a 128-week open-label study to assess the long-term safety and tolerabilty of the monoclonal antibody erenumab in migraine patients.
- Conditions
- Migraine, Migraine Disorders, Migraine Headache
- Trial name
- APOLLON (NCT04084314)
- Testing
- Erenumab
- Where
- 75 sites in Germany
- Volunteers
- 701 people
- Sponsor
- Novartis Pharmaceuticals
Migraine
Study Designed to Evaluate the Safety of Prophylactic Depakote ER in the Treatment of Adolescents With Migraine
The purpose of this study is to determine if long-term treatment, up to 1 year, with Depakote ER is safe in the reduction of occurrence of migraine headaches in adolescents.
- Trial name
- NCT00195806
- Testing
- divalproex sodium
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- Abbott
Obesity, Rhinitis
Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application
The purpose of this study is to study interactions between genes, lifestyle environmental factors like foods, nutritional supplements and non-invasive medical devices and health factors that can be measured without specialized…
- Conditions
- Obesity, Rhinitis, Rhinitis, Allergic, Respiratory Sounds
- Trial name
- NCT02758990
- Testing
- Vitamin A, Vitamin B6, Vitamin C
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Verifomics LLC
Migraine Disorders
Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine
This protocol describes the analysis of the Adelphi Real World (ARW) Migraine Disease Specific Programme(TM) 2022, a cross-sectional study which used both physician and patient surveys to assess the perception of the acute…
- Trial name
- Adelphi DSP (NCT06412965)
- Where
- United States
- Volunteers
- 528 people
- Sponsor
- Pfizer
Migraine Headache
Efficacy, Tolerability, and Safety of DFN-15
Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States
- Trial name
- NCT03009019
- Testing
- DFN-15 Active
- Where
- 43 sites in United States
- Volunteers
- 631 people
- Sponsor
- BioDelivery Sciences International
Migraine Disorders, Migraine
Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks
The purpose of this study is to determine the consistency of response for Treximet (sumatriptan/naproxen sodium), formerly known as Trexima, when treating four acute migraine attacks at the mild pain phase and within 1 hour of…
- Trial name
- NCT00240630
- Testing
- sumatriptan succinate/naproxen sodium
- Where
- 50 sites in United States
- Volunteers
- 646 people
- Sponsor
- GlaxoSmithKline
Episodic Migraine, Migraine With Aura
Mi-Helper Transnasal Cooling for Acute Treatment of Migraine
This is a prospective, double-blind, sham-controlled, randomized clinical trial . This study aims to assess the efficacy, safety, tolerability, and the optimal dose of the Mi-Helper transnasal cooling device for acute treatment…
- Conditions
- Episodic Migraine, Migraine With Aura, Migraine Without Aura, Migraine
- Trial name
- NCT06051604
- Testing
- Mi-Helper
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- CoolTech LLC
Migraine Disorders, Heart Septal Defects, Atrial
ESCAPE Migraine Trial
The purpose of this two arm controlled double-blind study is to determine the safety and effectiveness of PFO closure (closing a hole in the wall of the heart) in reducing the frequency of migraine headaches, in patients who…
- Trial name
- NCT00267371
- Testing
- PFO Closure with Premere investigational device., Medical management/current medications per standard of care by personal physician.
- Where
- 37 sites in United States
- Volunteers
- 168 people
- Sponsor
- Abbott Medical Devices
Migraine
Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071)
The purpose of this study is to test the effectiveness of a marketed drug in the treatment of a menstrual migraine attack.
- Trial name
- NCT00111709
- Testing
- MK0462, rizatriptan benzoate / Duration of Treatment -1 day
- Volunteers
- 393 people
- Sponsor
- Organon and Co
Migraine, Migraine With Aura
A Comprehensive Digital Care Program for Migraine Management
This study evaluates the clinical effectiveness of the Enso for Migraine program, a comprehensive digital care program combining an FDA-cleared neuromodulation wearable device (Enso), personalized exercise therapy, and a…
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- NCT07642414
- Testing
- Neuromodulation Wearable Device, Migraine Digital Care Program
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Hinge Health, Inc
Migraine With Aura, Migraine Without Aura
Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine
The purpose of this study is to evaluate the efficacy and safety of Laxymig® ER compared with placebo in prophylactic monotherapy treatment of migraine headache.
- Trial name
- NCT00334178
- Testing
- Laxymig ER (drug)
- Where
- 7 sites in Taiwan
- Volunteers
- 74 people
- Sponsor
- Lotus Pharmaceutical
Migraine
MLD10 in the Prevention of Migraine in Adults
This is a double-blind, placebo-controlled, randomized, multi-center study. Subjects agreeing to participate in the study and meet the entry criteria assessed at the screening visit, will begin a 28 day baseline period to confirm…
- Trial name
- NCT02322333
- Testing
- MLD10
- Where
- 9 sites in United States
- Volunteers
- 157 people
- Sponsor
- Pharmalyte Solutions LLC
Migraine
To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients
Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients.
- Trial name
- NCT02542605
- Testing
- Erenumab, PACAP-38 Challenge Agent
- Where
- 3 sites in United States, Belgium and 1 more
- Volunteers
- 35 people
- Sponsor
- Amgen
Migraine
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
This study is being conducted to evaluate the efficacy and tolerability of rimegepant in a population of adults that are unsuitable for triptan medications due to a previous intolerance, lack of efficacy, or contraindication…
- Trial name
- NCT05509400
- Testing
- Rimegepant
- Where
- 93 sites in United States, Australia and 13 more
- Volunteers
- 813 people
- Sponsor
- Pfizer
Migraine
AMG 334 20160172 Pediatric Migraine PK Study.
AMG 334 20160172 Pediatric Migraine PK Study.
- Trial name
- NCT03499119
- Testing
- AMG 334 Dose 1, AMG 334 Dose 2, AMG 334 Dose 3
- Where
- 14 sites in United States
- Volunteers
- 53 people
- Sponsor
- Amgen
Episodic Cluster Headache
A Study Of Galcanezumab In Participants With Episodic Cluster Headache
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as Galcanezumab in participants with episodic cluster headaches.
- Trial name
- NCT02397473
- Testing
- Galcanezumab
- Where
- 47 sites in United States, Belgium and 10 more
- Volunteers
- 109 people
- Sponsor
- Eli Lilly and Company
Cluster Headache
A Randomized Multicentre Study for the Acute Relief of Episodic and Chronic Cluster Headache.
The study will look at a non-invasive treatment for people suffering with chronic and episodic headaches. Study subjects will be randomized to an active treatment or an in-active treatment for 2 weeks.
- Trial name
- NCT01958125
- Testing
- gammaCore
- Where
- 9 sites in Denmark, Germany and 2 more
- Volunteers
- 102 people
- Sponsor
- ElectroCore INC
Migraine
Safety and Tolerability of Frovatriptan to Prevention of Menstrually Associated Migraine (MAM) Headaches
In this open-label, multi-center study, patients were treated with frovatriptan for a maximum of 12 perimenstrual periods (PMPs).
- Trial name
- MAM (NCT01035983)
- Testing
- Frovatriptan 2.5 mg
- Where
- 5 sites in Germany, Hungary and 3 more
- Volunteers
- 550 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram